Alexion Pharmaceuticals Stock Price - ALXN

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last: $ 99.51 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Alexion Pharmaceuticals Inc ALXN NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -5.30 -5.06% 99.51 104.90 99.41 102.80 104.81 16:41:46
Bid Price Ask Price Spread Spread % News
99.50 100.00 0.50 0.5% 2 4
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
24,857 2,706,424 $ 102.04 $ 276,162,558 2,424,061 92.56 - 141.86
Last Trade Time Type Quantity Stock Price Currency
16:41:17 50 $ 100.00 USD

Alexion Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 22.31B 224.23M $ 77.60M 0.33 16.50 221.77M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -7.00 1.10%

more financials information »

Alexion Pharmaceuticals News

Loading Messages....

Latest ALXN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALXN Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week96.46105.1394.5999.91282M3.053.16%
1 Month106.9107.8394.59100.44062M-7.39-6.91%
3 Months12512994.59107.50152M-25.49-20.39%
6 Months138.15139.9594.59115.07122M-38.64-27.97%
1 Year122.63141.8692.56117.23782M-23.12-18.85%
3 Years118.63149.3492.56120.69342M-19.12-16.12%
5 Years155.5208.8892.56133.93042M-55.99-36.01%

Alexion Pharmaceuticals Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.